Verona Pharma Stock Price, News & Analysis

Verona Pharma (Nasdaq: VRNA) will announce its financial results for Q3 and nine months ending September 30, 2021, on November 9, 2021, followed by a conference call at 9:00 a.m. EST. Investors can join via telephone or live webcast. Verona Pharma is developing ensifentrine, a novel therapy for respiratory diseases, currently in Phase 3 for COPD. The success of ensifentrine could make it the first dual-action treatment combining bronchodilation and anti-inflammatory effects. Further details available on their website.

Verona Pharma (Nasdaq: VRNA) announced Phase 2 data showing favorable effects of ensifentrine, delivered via a pressurized metered-dose inhaler (pMDI), on patients with moderate to severe chronic obstructive pulmonary disease (COPD). Presented at the CHEST Annual Meeting 2021, the study indicated significant improvements in lung function and tolerability akin to placebo. The ongoing global Phase 3 trial is expected to yield results in 2022. Ensifentrine is a first-in-class dual inhibitor of phosphodiesterase 3 and 4, promising both bronchodilator and anti-inflammatory effects.

Verona Pharma (Nasdaq: VRNA) announced the publication of an abstract regarding a study on the drug-drug interaction between fluconazole and ensifentrine, presented at the European Respiratory Society International Congress 2021. The Phase 1 study indicated that co-administration of fluconazole with nebulized ensifentrine showed minimal, clinically irrelevant effects on ensifentrine pharmacokinetics. The company continues its Phase 3 program for ensifentrine to treat COPD, with top-line results expected in 2022.

On August 31, 2021, Verona Pharma plc (Nasdaq: VRNA) announced that President and CEO David Zaccardelli will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on-demand starting at 7:00 AM EDT / 12:00 PM BST on September 13, 2021. A webcast of the event will be accessible for 90 days on the company's website. Verona Pharma focuses on innovative therapies for respiratory diseases, with its product candidate, ensifentrine, currently in clinical trials for COPD treatment.

Verona Pharma (Nasdaq: VRNA) reported financial results for Q2 2021, highlighting continued progress in its Phase 3 ENHANCE clinical program for ensifentrine in treating COPD. Despite COVID-19 challenges, patient enrollment is on track with ENHANCE-2 at 63% and ENHANCE-1 at 70%. The company announced a strategic collaboration with Nuance Pharma valued at up to $219 million for developing ensifentrine in Greater China. Financially, cash and equivalents stood at $146 million, but R&D expenses surged to $20.6 million, leading to a net loss of $22.1 million.

Verona Pharma (Nasdaq: VRNA) has announced that David Zaccardelli, CEO, will present at three virtual investor conferences in August 2021. The conferences include the BTIG Virtual Biotechnology Conference on August 9, the Wedbush PacGrow Healthcare Virtual Conference on August 11, and the Canaccord Genuity Growth Conference on August 12. Verona Pharma is advancing ensifentrine, a product candidate for respiratory diseases, currently in clinical trials, which could be a first-ever therapy combining bronchodilator and anti-inflammatory effects.

Verona Pharma (Nasdaq: VRNA) will report its financial results for the second quarter and the first half of 2021 on August 5, 2021. The company plans to host a conference call at 8:30 a.m. EDT to discuss the results and provide a corporate update. Verona Pharma focuses on developing innovative therapies for respiratory diseases, with its leading candidate, ensifentrine, currently in Phase 3 trials for COPD. Ensifentrine aims to combine bronchodilator and anti-inflammatory properties in a single treatment.

Verona Pharma has partnered with Nuance Pharma to develop and commercialize ensifentrine in Greater China. The agreement includes a $40 million upfront payment ($25 million cash, $15 million in equity) along with potential milestone payments up to $179 million and tiered royalties on net sales. Nuance Pharma will cover all development costs. Ensifentrine targets chronic obstructive pulmonary disease (COPD) and has shown promising results in clinical trials, offering both bronchodilator and anti-inflammatory effects.

Verona Pharma (Nasdaq: VRNA), a clinical-stage biopharmaceutical company, will have its CEO, David Zaccardelli, present an overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 9:00 AM ET. The event offers a significant platform for discussing the company's progress, particularly its innovative therapy, ensifentrine, aimed at treating respiratory diseases. A webcast of the presentation will be accessible on the company's website for 90 days following the event.